Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
115
Stocks News & Analysis
stocks
Finding value in the Aussie mining sector
stocks
Strong start to the year for cheap ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,800.40 | 36.00 | 0.41% |
| CAC 40 | 7,959.67 | 22.98 | -0.29% |
| DAX 40 | 23,239.18 | 147.31 | 0.64% |
| Dow JONES (US) | 46,548.50 | 303.09 | 0.66% |
| FTSE 100 | 9,534.91 | 4.80 | -0.05% |
| HKSE | 25,716.50 | 496.48 | 1.97% |
| NASDAQ | 22,855.19 | 582.10 | 2.61% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,499.85 | 80.45 | 0.60% |
| S&P 500 | 6,708.89 | 105.90 | 1.60% |
| S&P/ASX 200 | 8,525.10 | 33.40 | 0.39% |
| SSE Composite Index | 3,836.77 | 1.87 | 0.05% |